Cannabis for the Management of Cancer Symptoms: THC Version 2.0?

Overview

Journal Cannabis Cannabinoid Res

Specialty Pharmacology

Date 2018 May 24

PMID 29789813

Citations 12

Authors

Manuel Guzman

Affiliations

Soon will be listed here.

Citing Articles

Cytogenotoxicity and inflammatory response in liver of rats exposed to different doses of cannabis nano emulsions.

Pinto T, Rosario B, de Moraes Malinverni A, Xavier R, Martins Ferreira Y, Pisani L Arch Toxicol. 2024; 98(6):1877-1890.

PMID: 38494580 DOI: 10.1007/s00204-024-03712-7.

Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors.

Goulette M, Schlienz N, Case A, Hansen E, Rivard C, Ashare R Support Care Cancer. 2024; 32(4):210.

PMID: 38443674 PMC: 10915076. DOI: 10.1007/s00520-024-08374-w.

Effects of concomitant use of THC and irinotecan on tumour growth and biochemical markers in a syngeneic mouse model of colon cancer.

Zunec S, Karaconji I, catalinac M, Juric A, Katic A, Kozina G Arh Hig Rada Toksikol. 2023; 74(3):198-206.

PMID: 37791673 PMC: 10549892. DOI: 10.2478/aiht-2023-74-3765.

MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events.

To J, Davis M, Sbrana A, Alderman B, Hui D, Mukhopadhyay S Support Care Cancer. 2023; 31(4):202.

PMID: 36872397 DOI: 10.1007/s00520-023-07662-1.

In the Swim of Cannabis: Developmental Toxicity and Metabolomic Pathway Alterations of Zebrafish Larvae Exposed to THC for the Assessment of Its Potential Environmental and Human Health Impact.

Chatzimitakos T, Chousidis I, Leonardos D, Stalikas C, Leonardos I Molecules. 2022; 27(17).

PMID: 36080275 PMC: 9458094. DOI: 10.3390/molecules27175506.

References

Bar-Lev Schleider L, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O . Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med. 2018; 49:37-43. DOI: 10.1016/j.ejim.2018.01.023. View

Abrams D, Couey P, Shade S, Kelly M, Benowitz N . Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011; 90(6):844-51. DOI: 10.1038/clpt.2011.188. View

Lynch M, Clark A . Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. J Pain Symptom Manage. 2003; 25(6):496-8. DOI: 10.1016/s0885-3924(03)00142-8. View

Mechoulam R, Hanus L, Pertwee R, Howlett A . Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 2014; 15(11):757-64. DOI: 10.1038/nrn3811. View

Powell D, Pacula R, Jacobson M . Do medical marijuana laws reduce addictions and deaths related to pain killers?. J Health Econ. 2018; 58:29-42. PMC: 7867411. DOI: 10.1016/j.jhealeco.2017.12.007. View

Russo E . Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011; 163(7):1344-64. PMC: 3165946. DOI: 10.1111/j.1476-5381.2011.01238.x. View

Reiman A, Welty M, Solomon P . Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report. Cannabis Cannabinoid Res. 2017; 2(1):160-166. PMC: 5569620. DOI: 10.1089/can.2017.0012. View

Pertwee R, Howlett A, Abood M, Alexander S, Di Marzo V, Elphick M . International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev. 2010; 62(4):588-631. PMC: 2993256. DOI: 10.1124/pr.110.003004. View

Englund A, Freeman T, Murray R, McGuire P . Can we make cannabis safer?. Lancet Psychiatry. 2017; 4(8):643-648. DOI: 10.1016/S2215-0366(17)30075-5. View

10.

Bradford A, Bradford W . Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. Health Aff (Millwood). 2016; 35(7):1230-6. DOI: 10.1377/hlthaff.2015.1661. View

11.

Pacher P, Batkai S, Kunos G . The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58(3):389-462. PMC: 2241751. DOI: 10.1124/pr.58.3.2. View